{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.08","value":"0.538"},{"groupId":"OG001","spread":"2.45","value":"1.09"},{"groupId":"OG002","spread":"0","value":"0"},{"groupId":"OG003","spread":"3.02","value":"1.51"},{"groupId":"OG004","spread":"91.1","value":"54.2"},{"groupId":"OG005","spread":"45","value":"14.6"},{"groupId":"OG006","spread":"0","value":"0"},{"comment":"Dose dependent parameter and overall summary not provided.","groupId":"OG007","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"49"}],"units":"Participants"}],"description":"Minimum observed plasma concentration measured at steady state (Day 15). Study drug was administered with 240 mL of water. Summary of Steady-State, Day 15, was evaluated by dosing regimen.","dispersionType":"Standard Deviation","groups":[{"description":"INCB054329 Monotherapy","id":"OG000","title":"INCB054329 Monotherapy - 15 mg QD"},{"description":"INCB054329 Monotherapy","id":"OG001","title":"INCB054329 Monotherapy - 15 mg BID"},{"description":"INCB054329 Monotherapy","id":"OG002","title":"INCB054329 Monotherapy - 22.5 mg QD"},{"description":"INCB054329 Monotherapy","id":"OG003","title":"INCB054329 Monotherapy - 30 mg QD"},{"description":"INCB054329 Monotherapy","id":"OG004","title":"INCB054329 Monotherapy - 20 mg BID"},{"description":"INCB054329 Monotherapy","id":"OG005","title":"INCB054329 Monotherapy - 22.5 mg BID"},{"description":"INCB054329 Monotherapy","id":"OG006","title":"INCB054329 Monotherapy - 25 mg BID"},{"description":"INCB054329 Monotherapy","id":"OG007","title":"INCB054329 Monotherapy - Overall Dosing Regimen"}],"paramType":"MEAN","populationDescription":"All enrolled patients who received at least 1 dose of study medication and provided at least 1 plasma sample were included.","reportingStatus":"POSTED","timeFrame":"Summary of steady-state PK parameters by dosing regimen at Day 15","title":"Minimum Observed Plasma Concentration Over the Dose Interval (Cmin) Analysis of INCB054329","type":"SECONDARY","unitOfMeasure":"nM"}